NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

3D細胞培養的全球市場(第3版):主要地區的支架類型,產品,用途,目的和行業趨勢及預測(2020-2030年)

3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions: Industry Trends and Global Forecasts (3rd Edition), 2020-2030

出版商 Roots Analysis 商品編碼 973922
出版日期 內容資訊 英文 516 Pages
商品交期: 最快1-2個工作天內
價格
3D細胞培養的全球市場(第3版):主要地區的支架類型,產品,用途,目的和行業趨勢及預測(2020-2030年) 3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions: Industry Trends and Global Forecasts (3rd Edition), 2020-2030
出版日期: 2020年10月01日內容資訊: 英文 516 Pages
簡介

隨著生物技術和材料科學的進步,開發各種3D(3D)細胞培養模型成為可能。這些系統已被證明能夠更準確地模擬自然組織的微環境,這有助於克服與2D系統相關的大多數挑戰。

此外,3D細胞培養可以更好地模擬天然組織的微環境,使其更適合用於實驗研究,例如藥物發現/毒性測試,再生藥物開發,組織工程和乾細胞研究。用作良好的體內模型。預計這將有助於在不久的將來採用此類解決方案。

另外,最近的一項研究使用3D培養系統來模擬人支氣管組織和氣道細胞,以研究傳染性呼吸道疾病。此外,已經開發了3D細胞培養和基於類器官的篩選系統,以促進對新冠狀病毒病原學的研究並支持在這方面正在進行的藥物開發工作。 COVID-19大流行可能會增加對此類解決方案的需求,並為進入市場的人提供有利的機會,並且整個3D細胞培養市場在未來幾年中將顯著增長。可以預料的。

該報告調查了全球3D細胞培養市場,以及按技術開發,融資和投資,專利分析,業務部門,3D細胞培養格式,產品類型,應用領域,目的和地區劃分的市場。它提供信息,例如分析,競爭情況和主要公司的概況。

目錄

第1章序言

  • 調查範圍
  • 調查方法
  • 回答了重要問題
  • 本章概述

第2章執行摘要

第3章簡介

  • 本章概述
  • 細胞培養類型
  • 培養中的細胞形態
  • 從2D到3D細胞培養的過渡
  • 3D細胞培養概述
  • 細胞培養的建立和維持
  • 維持細胞培養健康的要求
  • 需要3D細胞培養系統
  • 3D細胞培養系統的優點和局限性
  • 未來展望

第4章3D細胞培養系統的分類

  • 3D細胞培養分類
  • 支架式3D細胞培養
    • 水凝膠/ECM類似物
    • 固體腳手架
    • 微圖案表面
    • 微載體
  • 非支架式3D細胞培養
    • 防粘表面
    • 浮動文化體系
    • 微流體表面和Organs-on-Chip
    • 3D生物反應器
  • 類器官

第5章3D矩陣和支架的製造

  • 本章概述
  • 如何製作多孔支架
  • 纖維支架的製造方法
  • 如何製作水凝膠
  • 如何製作定制支架
  • 如何製作微球
  • 如何製作本地支架

第6章3D細胞培養系統:開發人員狀況

  • 本章概述
  • 市場總體情況
    • 成立年份分析
    • 按公司規模分析
    • 總公司所在地分析
    • 按3D細胞培養格式進行分析
    • 按產品類型分析
  • 熱圖表示:3D細胞培養格式和總部位置分析
  • 樹狀圖表示:按公司規模和產品類型分析
  • 世界地圖上的表示形式:按地區總部所在地進行的分析
  • 3D細胞培養:服務提供商列表
  • 3D細胞培養:測定,試劑盒,試劑清單

第7章市場情況:腳手架類產品

  • 本章概述
  • 市場總體情況
    • 按發展狀況分析
    • 按產品類型分析
    • 按來源分析3D培養細胞
    • 通過製造中使用的方法進行分析
    • 按製造中使用的材料進行分析
    • 3D培養細胞的產品類型和來源分析
    • 按產品類型和製造方法分析
  • 開發人員情況
    • 成立年份分析
    • 按公司規模分析
    • 總公司所在地分析
  • 主要開發商:腳手架產品數量分析
  • 樹狀圖:按產品類型和公司規模分析

第8章市場情況:非腳手架類產品

  • 本章概述
  • 市場總體情況
    • 按發展狀況分析
    • 按產品類型分析
    • 通過原材料分析3D培養細胞
    • 通過製造中使用的方法進行分析
    • 按製造中使用的材料進行分析
    • 產品類型和按原材料分析3D培養細胞
    • 按產品類型和製造方法分析
  • 開發人員情況
    • 成立年份分析
    • 按公司規模分析
    • 總公司所在地分析
  • 主要開發商:按非腳手架產品數量進行分析
  • 樹狀圖表示:按產品類型和公司規模分析

第9章市場情況:生物反應器

  • 本章概述
  • 3D生物反應器:總體市場情況
    • 按3D生物反應器類型分析
    • 按工作量分析
  • 3D生物反應器:開發人員情況
    • 成立年份分析
    • 按公司規模分析
    • 總公司所在地分析
  • 主要開發商:按3D生物反應器數量分析

第10章主要應用程序

  • 本章概述
  • 癌症研究
  • 藥物發現和毒性篩選
  • 幹細胞研究
  • 再生醫學和組織工程
  • 3D細胞培養系統:按主要應用領域分析

第11章公司簡介概述:支架式產品(水凝膠/ECM顯影劑)

  • 本章概述
    • 3D Biotek
    • Advanced BioMatrix
    • Alphabioregen
    • Corning Life Sciences
    • REPROCELL

第12章企業概況概述:非支架式產品(ORGAN-ON-CHIP開發人員)

  • 本章概述
    • CN Bio Innovations
    • Emulate
    • InSphero
    • Mimetas
    • TissUse

第13章公司概況:3D生物反應器

  • 本章概述
  • BISS TGT
  • Celartia
  • Cell Culture
  • Cesco Bioengineering
  • Flexcell International
  • PBS Biotech
  • Synthecon

第14章融資和投資分析

  • 本章概述
  • 資金類型
  • 3D細胞培養系統:融資和投資分析
    • 按融資實例數量分析
    • 按投資額分析
    • 按資金類型分析
    • 通過3D細胞培養格式進行分析
    • 按產品類型分析
    • 區域分析
    • 活躍公司:按融資實例數量分析
    • 活躍公司:按資金數量分析
    • 活躍投資者:按實例數量分析
  • 結論

第15章聯盟與合作

  • 本章概述
  • 夥伴關係模型
  • 3D細胞培養系統:最近的合作夥伴關係和合作
    • 聯盟年度分析
    • 結合類型分析
    • 通過3D細胞培養格式進行分析
    • 按產品類型分析
    • 活躍公司:按聯盟數量分析
    • 區域分析
    • 洲際和洲際協議

第16章專利分析

  • 本章概述
  • 範圍和調查方法
  • 3D細胞培養系統:專利分析
    • 按專利類型分析
    • 按發行年份分析
    • 發行機構分析
    • 按CPC符號分析
    • 新的優先領域
    • 主要公司:按專利數量分析
  • 3D細胞培養系統:專利評估分析
  • 主要專利:按引文數量分析

第17章市場預測

  • 本章概述
  • 預測性研究方法和關鍵前提
  • COVID-19大流行對全球市場的影響
  • 全球3D細胞培養市場(2020-2030)
  • 按業務部門
    • 3D細胞培養系統
    • 3D細胞培養耗材
    • 3D細胞培養服務
  • 通過3D細胞培養格式
    • 腳手架類型
    • 非腳手架類型
    • 3D生物反應器
  • 按產品類型
    • 防粘表面
    • 水凝膠/ECM
    • 微圖案表面
    • 微載體
    • 微流體系統
    • 固體腳手架
    • 懸浮培養系統
  • 按應用領域
    • 癌症調查
    • 藥物發現和毒性測試
    • 幹細胞研究
    • 再生醫學和組織工程
  • 有目的
    • 用於研究
    • 治療
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和北非
    • 其他地區
  • 按大公司劃分(2020)
  • 結論

第18章調查分析

  • 本章概述
  • 受訪者摘要
  • 研究見解
    • 3D細胞培養格式
    • 提供的產品類型
    • 產品開發現狀
    • 用於3D培養細胞的材料
    • 用於製造的方法
    • 使用範圍
    • 為3D細胞培養提供的服務
    • 當前和未來的市場機會

第19章結論

第20章執行人員見解

  • 本章概述
  • Cellendes
  • Synthecon
  • BRTI Life Sciences
  • Kirkstall
  • QGel
  • Xylyx Bio
  • InSphero
  • GSI
  • Nanofiber Solutions、ナろ

第21章附錄I:匯總數據

第22章附錄II:公司和組織列表

目錄

Title:
3D Cell Culture Market
by Scaffold Format (Scaffold Based / Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Microfluidic System, Microcarrier, Organ-on-Chip and Others), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions: Industry Trends and Global Forecasts (3rd Edition), 2020-2030.

Overview:

Animal cell cultures represent an integral part of the drug discovery and development process. The conventional 2 dimensional (2D) cell culturing format is still extensively used in early stage research and is instrumental in establishing initial proof-of-concept and validating mechanisms of action of pharmacological leads. However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research . This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases . Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

Scope of the Report:

The "3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030" report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:

  • An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.
  • A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence.
  • A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence.
  • A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence.
  • An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.
  • Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook.
  • An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.
  • An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.
  • An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.
  • An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.
  • An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.
  • Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:

  • Brigitte Angres (Co-founder, Cellendes)
  • Bill Anderson (President and CEO, Synthecon)
  • Anonymous (President and CEO, Anonymous)
  • Anonymous (Co-founder and Vice President, Anonymous)
  • Scott Brush (Vice President, BRTI Life Sciences)
  • Malcolm Wilkinson (Managing Director, Kirkstall)
  • Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
  • Tanya Yankelevich (Director, Xylyx Bio)
  • Jens Kelm (Chief Scientific Officer, InSphero)
  • Walter Tinganelli (Group Leader, GSI)
  • Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading industry players engaged in the development of 3D cell culture products?
  • What are the most popular 3D cell culture products?
  • What are the different applications for which 3D cell culture products are currently being developed?
  • What are the key factors that are likely to influence the evolution of this market?
  • What is the trend of capital investments in the 3D cell culture systems market?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • How is the COVID-19 pandemic likely to impact the 3D cell culture systems market?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to 3D cell culture systems market?

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term.

Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis.

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions)

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Types of Cell Cultures
    • 3.2.1. Primary Cell Cultures
    • 3.2.2. Cell Lines
  • 3.3. Morphology of Cells in Culture
  • 3.4. Transition from 2D to 3D Cell Cultures
  • 3.5. Overview of 3D Cell Culturing
    • 3.5.1. Components of the Extracellular Matrix (ECM)
    • 3.5.2. In Vitro Cell Culturing
    • 3.5.3. Selection of Culture Format
  • 3.6. Establishment and Maintenance of Cell Cultures
    • 3.6.1. Isolating Cells from Tissues
    • 3.6.2. Maintaining Cells in Culture
    • 3.6.3. Sub-Culturing / Passaging
    • 3.6.4. Cryogenic Storage
  • 3.7. Requirements for Maintaining the Health of Cell Cultures
    • 3.7.1. Safety Guidelines in a Cell Culture Facility
    • 3.7.2. Cell Culture Health and Optimal Conditions for Growth
    • 3.7.3. Concerns Related to Cross Contamination
    • 3.7.4. Methods to Prevent Contamination
  • 3.8. Need for 3D Cell Culture Systems
    • 3.8.1. Model Systems
    • 3.8.2. Drug Discovery and Preclinical Research
    • 3.8.3. Cancer Research
    • 3.8.4. Virology Research
    • 3.8.5. Genetic Engineering and Gene Therapy Research
  • 3.9. Advantages and Limitations of 3D Cell Culture Systems
  • 3.10. Future Perspectives

4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS

  • 4.1. 3D Cell Culture Classification
  • 4.2. Scaffold based 3D Cell Cultures
    • 4.2.1. Hydrogels / ECM Analogs
    • 4.2.2. Solid Scaffolds
    • 4.2.3. Micropatterned Surfaces
    • 4.2.4. Microcarriers
  • 4.3. Scaffold Free 3D Cell Cultures
    • 4.3.1. Attachment Resistant Surfaces
    • 4.3.2. Suspension Culture Systems
      • 4.3.2.1. Hanging Drop Plates
      • 4.3.2.2. Magnetic Levitation and 3D Bioprinting
    • 4.3.3. Microfluidic Surfaces and Organs-on-Chips
    • 4.3.4. 3D Bioreactors
  • 4.4. Organoids

5. FABRICATION OF 3D MATRICES AND SCAFFOLDS

  • 5.1. Chapter Overview
  • 5.2. Methods for Fabricating Porous Scaffolds
    • 5.2.1. Particulate Leaching
    • 5.2.2. Solvent Casting
    • 5.2.3. Emulsion Templating
    • 5.2.4. Gas Foaming
    • 5.2.5. Melt Molding
    • 5.2.6. Microsphere Sintering
  • 5.3. Methods for Fabricating Fibrous Scaffolds
    • 5.3.1. Electrospinning
    • 5.3.2. Phase Separation
    • 5.3.3. Self-Assembly
    • 5.3.4. Fiber Mesh and Fiber Bonding
  • 5.4. Methods for Fabricating Hydrogels
    • 5.4.1. Gelation
    • 5.4.2. Solvent Casting and Particulate Leaching
    • 5.4.3. Gas Foaming
    • 5.4.4. Freeze Drying
    • 5.4.5. Co-polymerization / Crosslinking Methods
    • 5.4.6. Microfluidics
  • 5.5. Methods for Fabricating Custom Scaffolds
    • 5.5.1. Stereo-Lithography
    • 5.5.2. 3D Bioprinting and Selective Laser Sintering (SLS)
    • 5.5.3. Fused Deposition Modeling
    • 5.5.4. Membrane Lamination
    • 5.5.5. Rapid Prototyping / Solid Free-Form Technique
  • 5.6. Methods for Fabricating Microspheres
    • 5.6.1. Solvent Evaporation
    • 5.6.2. Single and Double Emulsification
    • 5.6.3. Particle Aggregation
  • 5.7. Methods for Fabricating Native Scaffolds
    • 5.7.1. Decellularization

6. 3D CELL CULTURE SYSTEMS: DEVELOPER LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. 3D Cell Culture System Developers: Overall Market Landscape
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Location of Headquarters
    • 6.2.4. Analysis by 3D Cell Culture Format
    • 6.2.5. Analysis by Type of Product
  • 6.3. Heat Map Representation: Analysis by 3D Cell Culture Format and Location of Headquarters
  • 6.4. Tree Map Representation: Analysis by Company Size and Type of Product
  • 6.5. World Map Representation: Analysis by Location of Regional Headquarters
  • 6.6. 3D Cell Cultures: List of Service Providers
  • 6.7. 3D Cell Cultures: List of Assays, Kits and Reagents

7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS

  • 7.1. Chapter Overview
  • 7.2. Scaffold based Products: Overall Market Landscape
    • 7.2.1. Analysis by Status of Development
    • 7.2.2. Analysis by Type of Product
    • 7.2.3. Analysis by Source of 3D Cultured Cells
    • 7.2.4. Analysis by Method Used for Fabrication
    • 7.2.5. Analysis by Material Used for Fabrication
    • 7.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
    • 7.2.7. Analysis by Type of Product and Method Used for Fabrication
  • 7.3. Scaffold Based Products: Developer Landscape
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
  • 7.4. Leading Developers: Analysis by Number of Scaffold based Products
  • 7.5. Tree Map Representation: Analysis by Type of Product and Company Size

8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS

  • 8.1. Chapter Overview
  • 8.2. Scaffold Free Products: Overall Market Landscape
    • 8.2.1. Analysis by Status of Development
    • 8.2.2. Analysis by Type of Product
    • 8.2.3. Analysis by Source of 3D Cultured Cells
    • 8.2.4. Analysis by Method Used for Fabrication
    • 8.2.5. Analysis by Material Used for Fabrication
    • 8.2.6. Analysis by Type of Product and Source of 3D Cultured Cells
    • 8.2.7. Analysis by Type of Product and Method Used for Fabrication
  • 8.3. Scaffold Free Products: Developer Landscape
    • 8.3.1. Analysis by Year of Establishment
    • 8.3.2. Analysis by Company Size
    • 8.3.3. Analysis by Location of Headquarters
  • 8.4. Leading Developers: Analysis by Number of Scaffold Free Products
  • 8.5. Tree Map Representation: Analysis by Type of Product and Company Size

9. MARKET LANDSCAPE: 3D BIOREACTORS

  • 9.1. Chapter Overview
  • 9.2. 3D Bioreactors: Overall Market Landscape
    • 9.2.1. Analysis by Type of 3D Bioreactor
    • 9.2.2. Analysis by Working Volume
  • 9.3. 3D Bioreactors: Developer Landscape
    • 9.3.1. Analysis by Year of Establishment
    • 9.3.2. Analysis by Company Size
    • 9.3.3. Analysis by Location of Headquarters
  • 9.4. Leading Developers: Analysis by Number of 3D Bioreactors

10. KEY APPLICATION AREAS

  • 10.1. Chapter Overview
  • 10.2. 3D Cell Culture Systems in Cancer Research
    • 10.2.1. Need for 3D Culture Systems in Cancer Research
      • 10.2.1.1. Improving Cancer Drug Screening with 3D Culture Systems
  • 10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
    • 10.3.1. Drug Development Studies
    • 10.3.2. Toxicity Screening
      • 10.3.2.1. 3D Liver Models
      • 10.3.2.2. Other 3D Models
  • 10.4. 3D Cell Culture Systems in Stem Cell Research
    • 10.4.1. Potential of 3D Culture Systems in Stem Cell Differentiation
    • 10.4.2. In Vitro 3D Microenvironment to Induce Embryoid Body Formation
  • 10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering
  • 10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
    • 10.6.1. 3D Cell Culture Systems: Analysis by Key Application Areas and 3D Cell Culture Format
      • 10.6.1.1. Scaffold based 3D Products: Analysis by Key Application Areas
      • 10.6.1.2. Scaffold Free 3D Products: Analysis by Key Application Areas
      • 10.6.1.3. 3D Bioreactors: Analysis by Key Application Areas

11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)

  • 11.1. Chapter Overview
    • 11.1.1. 3D Biotek
      • 11.1.1.1. Company Overview
      • 11.1.1.2. Product Portfolio
      • 11.1.1.3. Recent Developments and Future Outlook
    • 11.1.2. Advanced BioMatrix
      • 11.1.2.1. Company Overview
      • 11.1.2.2. Product Portfolio
      • 11.1.2.3. Recent Development and Future Outlook
    • 11.1.3. Alphabioregen
      • 11.1.3.1. Company Overview
      • 11.1.3.2. Product Portfolio
      • 11.1.3.3. Recent Developments and Future Outlook
    • 11.1.4. Corning Life Sciences
      • 11.1.4.1. Company Overview
      • 11.1.4.2. Product Portfolio
      • 11.1.4.3. Recent Developments and Future Outlook
    • 11.1.5. REPROCELL
      • 11.1.5.1. Company Overview
      • 11.1.5.2. Product Portfolio
      • 11.1.5.3. Recent Developments and Future Outlook

12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIP DEVELOPERS)

  • 12.1. Chapter Overview
    • 12.1.1. CN Bio Innovations
      • 12.1.1.1. Company Overview
      • 12.1.1.2. Financial Information
      • 12.1.1.3. Product Portfolio
      • 12.1.1.4. Recent Developments and Future Outlook
    • 12.1.2. Emulate
      • 12.1.2.1. Company Overview
      • 12.1.2.2. Financial Information
      • 12.1.2.3. Product Portfolio
      • 12.1.2.4. Recent Developments and Future Outlook
    • 12.1.3. InSphero
      • 12.1.3.1. Company Overview
      • 12.1.3.2. Financial Information
      • 12.1.3.3. Product Portfolio
      • 12.1.3.4. Recent Developments and Future Outlook
    • 12.1.4. Mimetas
      • 12.1.4.1. Company Overview
      • 12.1.4.2. Financial Information
      • 12.1.4.3. Product Portfolio
      • 12.1.4.4. Recent Developments and Future Outlook
    • 12.1.5. TissUse
      • 12.1.5.1. Company Overview
      • 12.1.5.2. Product Portfolio
      • 12.1.5.3. Recent Developments and Future Outlook

13. COMPANY PROFILES: 3D BIOREACTORS

  • 13.1. Chapter Overview
  • 13.2. BISS TGT
    • 13.2.1. Company Overview
    • 13.2.2. Product Portfolio
    • 13.2.3. Recent Developments and Future Outlook
  • 13.3. Celartia
    • 13.3.1. Company Overview
    • 13.3.2. Product Portfolio
    • 13.3.3. Recent Developments and Future Outlook
  • 13.4. Cell Culture
    • 13.4.1. Company Overview
    • 13.4.2. Product Portfolio
    • 13.4.3. Recent Developments and Future Outlook
  • 13.5. Cesco Bioengineering
    • 13.5.1. Company Overview
    • 13.5.2. Product Portfolio
    • 13.5.3. Recent Developments and Future Outlook
  • 13.6. Flexcell International
    • 13.6.1. Company Overview
    • 13.6.2. Product Portfolio
    • 13.6.3. Recent Developments and Future Outlook
  • 13.7. PBS Biotech
    • 13.7.1. Company Overview
    • 13.7.2. Product Portfolio
    • 13.7.3. Recent Developments and Future Outlook
  • 13.8. Synthecon
    • 13.8.1. Company Overview
    • 13.8.2. Product Portfolio
    • 13.8.3. Recent Developments and Future Outlook

14. FUNDING AND INVESTMENT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Types of Funding
  • 14.3. 3D Cell Culture Systems: Funding and Investment Analysis
    • 14.3.1. Analysis by Number of Funding Instances
    • 14.3.2. Analysis by Amount Invested
    • 14.3.3. Analysis by Type of Funding
    • 14.3.4. Analysis by 3D Cell Culture Format
    • 14.3.5. Analysis by Type of Product
    • 14.3.6. Analysis by Geography
    • 14.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 14.3.8. Most Active Players: Analysis by Amount of Funding
    • 14.3.9. Most Active Investors: Analysis by Number of Instances
  • 14.4 Concluding Remarks

15. PARTNERSHIPS AND COLLABORATIONS

  • 15.1. Chapter Overview
  • 15.2. Partnership Models
  • 15.3. 3D Cell Culture Systems: Recent Partnerships and Collaborations
    • 15.3.1. Analysis by Year of Partnership
    • 15.3.2. Analysis by Type of Partnership
      • 15.3.2.1. Analysis by Year of Partnership and Type of Partnership
      • 15.3.2.2. Analysis by Company Size and Type of Partnership
    • 15.3.3. Analysis by Type of Partner
      • 15.3.3.1. Analysis by Year of Partnership and Type of Partner
      • 15.3.3.2. Analysis by Type of Partnership and Type of Partner
    • 15.3.4. Analysis by 3D Cell Culture Format
      • 15.3.4.1. Analysis by Year of Partnership and 3D Cell Culture Format
      • 15.3.4.2. Analysis by Type of Partnership and 3D Cell Culture Format
    • 15.3.5. Analysis by Type of Product
      • 15.3.5.1. Analysis by Year of Partnership and Type of Product
      • 15.3.5.2. Analysis by Type of Partnership and Type of Product
    • 15.3.6. Most Active Players: Analysis by Number of Partnerships
    • 15.3.7. Regional Analysis
    • 15.3.8. Intercontinental and Intracontinental Agreements

16. PATENT ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Scope and Methodology
  • 16.3. 3D Cell Culture Systems: Patent Analysis
    • 16.3.1. Analysis by Type of Patent
    • 16.3.2. Analysis by Publication Year
    • 16.3.3. Analysis by Issuing Authority
    • 16.3.4. Analysis by CPC Symbols
    • 16.3.5. Emerging Focus Area
    • 16.3.6. Leading Players: Analysis by Number of Patents
  • 16.4. 3D Cell Culture Systems: Patent Valuation Analysis
  • 16.5. Leading Patents: Analysis by Number of Citations

17. MARKET FORECAST

  • 17.1. Chapter Overview
  • 17.2. Forecast Methodology and Key Assumptions
  • 17.3. Impact of COVID-19 Pandemic on Global 3D Cell Culture Market
  • 17.4. Global 3D Cell Culture Market, 2020-2030
  • 17.5. Global 3D Cell Culture Market: Distribution by Business Segment
    • 17.5.1. 3D Cell Culture Systems Market, 2020-2030
    • 17.5.2. 3D Cell Culture Consumables Market, 2020-2030
    • 17.5.3. 3D Cell Culture Services Market, 2020-2030
  • 17.6. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
    • 17.6.1. 3D Cell Culture Systems Market for Scaffold based Products, 2020-2030
    • 17.6.2. 3D Cell Culture Systems Market for Scaffold Free Products, 2020-2030
    • 17.6.3. 3D Cell Culture Systems Market for 3D Bioreactors, 2020-2030
  • 17.7. Global 3D Cell Culture Systems Market: Distribution by Type of Product
    • 17.7.1. 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2020-2030
    • 17.7.2. 3D Cell Culture Systems Market for Hydrogels / ECMs, 2020-2030
    • 17.7.3 3D Cell Culture Systems Market for Micropatterned Surface, 2020-2030
    • 17.7.4. 3D Cell Culture Systems Market for Microcarriers, 2020-2030
    • 17.7.5. 3D Cell Culture Systems Market for Microfluidic Systems, 2020-2030
    • 17.7.6. 3D Cell Culture Systems Market for Solid Scaffolds, 2020-2030
    • 17.7.7. 3D Cell Culture Systems Market for Suspension Culture Systems, 2020-2030
  • 17.8. Global 3D Cell Culture Systems Market: Distribution by Area of Application
    • 17.8.1. 3D Cell Culture Systems Market for Cancer Research, 2020-2030
    • 17.8.2 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2020-2030
    • 17.8.3. 3D Cell Culture Systems Market for Stem Cell Research, 2020-2030
    • 17.8.4. 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2020-2030
  • 17.9. Global 3D Cell Culture Systems Market: Distribution by Purpose
    • 17.9.1. 3D Cell Culture Systems Market for Research Use, 2020-2030
    • 17.9.2 3D Cell Culture Systems Market for Therapeutic Use, 2020-2030
  • 17.10. Global 3D Cell Culture Systems Market: Distribution by Geography
    • 17.10.1. 3D Cell Culture Systems Market in North America, 2020-2030
    • 17.10.2 3D Cell Culture Systems Market in Europe, 2020-2030
    • 17.10.3. 3D Cell Culture Systems Market in Asia-Pacific, 2020-2030
    • 17.10.4. 3D Cell Culture Systems Market in Latin America, 2020-2030
    • 17.10.4. 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2020-2030
    • 17.10.5. 3D Cell Culture Systems Market in Rest of the World, 2020-2030
  • 17.11. Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
  • 17.12. Concluding Remarks

18. SURVEY ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Overview of Respondents
    • 18.2.1. Designation of Respondents
  • 18.3. Survey Insights
    • 18.3.1. 3D Cell Culture Format
    • 18.3.2. Type of Product(s) Offered
    • 18.3.3. Status of Development of Product(s)
    • 18.3.4. Source of 3D Cultured Cells
    • 18.3.5. Method Used for Fabrication
    • 18.3.6. Area(s) of Application
    • 18.3.7. Services Offered for 3D Cell Cultures
    • 18.3.8. Current and Future Market Opportunity

19. CONCLUSION

20. EXECUTIVE INSIGHTS

  • 20.1. Chapter Overview
  • 20.2. Cellendes
    • 20.2.1. Company Snapshot
    • 20.2.2. Interview Transcript: Brigitte Angres, Co-founder
  • 20.3. Synthecon
    • 20.3.1. Company Snapshot
    • 20.3.2. Interview Transcript: Bill Anderson, President and CEO
  • 20.4. Anonymous
    • 20.4.1. Interview Transcript: Anonymous, President and CEO
  • 20.5. Anonymous
    • 20.5.1. Interview Transcript: Anonymous, Co-founder and Vice President
  • 20.6. BRTI Life Sciences
    • 20.6.1. Company Snapshot
    • 20.6.2. Interview Transcript: Scott Brush, Vice President
  • 20.7. Kirkstall
    • 20.7.1. Company Snapshot
    • 20.7.2. Interview Transcript: Malcolm Wilkinson, Managing Director
  • 20.8. QGel
    • 20.8.1. Company Snapshot
    • 20.8.2. Interview Transcript: Ryder Clifford, Director and Simone Carlo Rizzi, Chief Scientific Officer
  • 20.9. Xylyx Bio
    • 20.9.1. Company Snapshot
    • 20.9.2. Interview Transcript: Tanya Yankelevich, Director
  • 20.10. InSphero
    • 20.10.1. Company Snapshot
    • 20.10.2. Interview Transcript: Jens Kelm, Chief Scientific Officer
  • 20.11. GSI
    • 20.11.1. Company Snapshot
    • 20.11.2. Interview Transcript: Walter Tinganelli, Group Leader
  • 20.12. Nanofiber Solutions
    • 20.12.1. Company Snapshot
    • 20.12.2. Interview Transcript: Darlene Thieken, Project Manager

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1: Classification of Cell Cultures
  • Figure 3.2: Types of 2D and 3D Cell Culture Systems
  • Figure 3.3: Key Components of ECM
  • Figure 3.4: Factors Influencing the Selection of 3D Cell Culture Systems
  • Figure 3.5: Methods Used for Isolation of Cells from Tissues
  • Figure 3.6: Methods Used for Cryogenic Storage
  • Figure 3.7: Required Biosafety Levels for Cell Cultures
  • Figure 3.8: Key Applications of Cell Cultures
  • Figure 3.9: Shapes of 3D Spheroids Generated via 3D Cell Culture Systems
  • Figure 3.10: Advantages and Limitations of 3D Cell Culture Systems
  • Figure 4.1: Classification of 3D Cell Culture Systems
  • Figure 4.2: Natural Components of ECM Used for Fabrication of Scaffolds
  • Figure 4.3: Advantages and Disadvantages of Hydrogels
  • Figure 4.4: Advantages of Microcarriers
  • Figure 4.5: Techniques Used for Formation of 3D Spheroids
  • Figure 4.6: Structures of Spinner Flask and Rotating Wall Bioreactors
  • Figure 6.1: 3D Cell Culture System Developers: Distribution by Year of Establishment
  • Figure 6.2: 3D Cell Culture System Developers: Distribution by Company Size
  • Figure 6.3: 3D Cell Culture System Developers: Distribution by Location of Headquarters
  • Figure 6.4: 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
  • Figure 6.5: 3D Cell Culture System Developers: Distribution by Type of Product
  • Figure 6.6: 3D Cell Culture System Developers: Distribution by Number of 3D Cell Culture Products
  • Figure 6.7: Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
  • Figure 6.8: Tree Map Representation: Distribution by Company Size and Type of Product
  • Figure 6.9: World Map Representation: Distribution by Location of Regional Headquarters
  • Figure 7.1: Scaffold Based Products: Distribution by Status of Development
  • Figure 7.2: Scaffold Based Products: Distribution by Type of Product
  • Figure 7.3: Scaffold Based Products: Distribution by Source of 3D Cultured Cells
  • Figure 7.4: Scaffold Based Products: Distribution by Method Used for Fabrication
  • Figure 7.5: Scaffold Based Products: Distribution by Material Used for Fabrication
  • Figure 7.6: Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
  • Figure 7.7: Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
  • Figure 7.8: Scaffold Based Product Developers: Distribution by Year of Establishment
  • Figure 7.9: Scaffold Based Product Developers: Distribution by Company Size
  • Figure 7.10: Scaffold Based Product Developers: Distribution by Location of Headquarters
  • Figure 7.11: Leading Developers: Distribution by Number of Scaffold Based Products
  • Figure 7.12: Tree Map Representation: Distribution by Type of Product and Company Size
  • Figure 8.1: Scaffold Free Products: Distribution by Status of Development
  • Figure 8.2: Scaffold Free Products: Distribution by Type of Product
  • Figure 8.3: Scaffold Free Products: Distribution by Source of 3D Cultured Cells
  • Figure 8.4: Scaffold Free Products: Distribution by Method Used for Fabrication
  • Figure 8.5: Scaffold Free Products: Distribution by Material Used for Fabrication
  • Figure 8.6: Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
  • Figure 8.7: Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
  • Figure 8.8: Scaffold Free Product Developers: Distribution by Year of Establishment
  • Figure 8.9: Scaffold Free Product Developers: Distribution by Company Size
  • Figure 8.10: Scaffold Free Product Developers: Distribution by Location of Headquarters
  • Figure 8.11: Leading Developers: Distribution by Number of Scaffold Free Products
  • Figure 8.12: Tree Map Representation: Distribution by Type of Product and Company Size
  • Figure 9.1: 3D Bioreactors: Distribution by Type of 3D Bioreactor
  • Figure 9.2: 3D Bioreactors: Distribution by Working Volume
  • Figure 9.3: 3D Bioreactor Developers: Distribution by Year of Establishment
  • Figure 9.4: 3D Bioreactor Developers: Distribution by Company Size
  • Figure 9.5: 3D Bioreactor Developers: Distribution by Location of Headquarters
  • Figure 9.6: Leading Developers: Distribution by Number of 3D Bioreactors
  • Figure 10.1: Key Application Areas of 3D Cell Culture Systems
  • Figure 10.2: 3D Cell Culture Systems in Cancer Research
  • Figure 10.3: 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
  • Figure 10.4: Methods Used for Embryoid Body Formation
  • Figure 10.5: Top-Down and Bottom-Up Approaches for Tissue Engineering
  • Figure 10.6: 3D Cell Culture Systems: Distribution by Key Application Areas
  • Figure 10.7: 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
  • Figure 10.8: Scaffold Based 3D Products: Distribution by Key Application Areas
  • Figure 10.9: Scaffold Free 3D Products: Distribution by Key Application Areas
  • Figure 10.10: 3D Bioreactors: Distribution by Key Application Areas
  • Figure 13.1: Key Features of 3D Perfusion Bioreactors
  • Figure 13.2: MagDrive and AirDrive Mechanisms for PBS Bioreactors
  • Figure 13.3: Advantages of Rotary Cell Culture System (RCCS)
  • Figure 14.1: Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015-Q3 2020
  • Figure 14.2: Funding and Investments: Cumulative Number of Funding Instances by Year, 2015 - Q3 2020
  • Figure 14.3: Funding and Investments: Cumulative Amount Invested, 2015 - Q3 2020 (USD Million)
  • Figure 14.4: Funding and Investments: Distribution of Instances by Type of Funding, 2015 - Q3 2020
  • Figure 14.5: Funding and Investments: Year-Wise Distribution of Instances and Type of Funding, 2015 - Q3 2020
  • Figure 14.6: Funding and Investments: Distribution by Amount Invested and Type of Funding, 2015 - Q3 2020 (USD Million)
  • Figure 14.7: Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 - Q3 2020
  • Figure 14.8: Funding and Investments: Distribution by Number of Instances and Amount Invested by 3D Cell Culture Format, 2015 - Q3 2020
  • Figure 14.9: Funding and Investments: Distribution by Number of Instances and Amount Invested by Type of Product, 2015 - Q3 2020
  • Figure 14.10: Funding and Investments: Distribution by Geography
  • Figure 14.11: Funding and Investments: Regional Distribution by Total Amount Invested, 2015 - Q3 2020
  • Figure 14.12: Most Active Players: Distribution by Number of Funding Instances, 2015 - Q3 2020
  • Figure 14.13: Most Active Players: Distribution by Amount Raised, 2015 - Q3 2020 (USD Million)
  • Figure 14.14: Most Active Investors: Distribution by Number of Funding Instances, 2015-Q3 2020
  • Figure 14.15: Funding and Investment Summary, 2015 - Q3 2020 (USD Million)
  • Figure 15.1: Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015 - Q3 2020
  • Figure 15.2: Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 15.3: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Figure 15.4: Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
  • Figure 15.5: Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 15.6: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 15.7: Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 15.8: Partnerships and Collaborations: Distribution by 3D Cell Culture Format
  • Figure 15.9: Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
  • Figure 15.10: Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
  • Figure 15.11: Partnerships and Collaborations: Distribution by Type of Product
  • Figure 15.12: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
  • Figure 15.13: Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
  • Figure 15.14: Most Active Players: Distribution by Number of Partnerships
  • Figure 15.15: Partnerships and Collaborations: Regional Distribution
  • Figure 15.16: Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
  • Figure 16.1: Patent Analysis: Distribution by Type of Patent
  • Figure 16.2: Patent Analysis: Cumulative Distribution by Publication Year, 2015 - Q3 2020
  • Figure 16.3: Patent Analysis: Distribution of Granted Patents by Publication Year, 2015 - Q3 2020
  • Figure 16.4: Patent Analysis: Distribution of Filed Patents Publication Year, 2015 - Q3 2020
  • Figure 16.5: Patent Analysis: Distribution by Patent Type and Publication Year, 2015 - Q3 2020
  • Figure 16.6: Patent Analysis: Distribution by Issuing Authority
  • Figure 16.7: Patent Analysis: Distribution by CPC Symbols
  • Figure 16.8: Patent Analysis: Distribution by Emerging Focus Area
  • Figure 16.9: Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2015 - Q3 2020
  • Figure 16.10: Leading Patent Assignees (Industry Players): Distribution by Number of Patents
  • Figure 16.11: Leading Patent Assignees (Non-Industry Players): Distribution by Number of Patents
  • Figure 16.12: Patent Analysis: Distribution by Patent Age, 2000-2020
  • Figure 16.13: Patent Analysis: Distribution by Proprietary Scoring Criteria
  • Figure 16.14: Patent Analysis: Valuation Analysis
  • Figure 17.1: Global 3D Cell Culture Market, 2020-2030 (USD Million)
  • Figure 17.2: Global 3D Cell Culture Market: Distribution by Business Segment, 2020 and 2030
  • Figure 17.3: 3D Cell Culture Systems Market, 2020-2030 (USD Million)
  • Figure 17.4: 3D Cell Culture Consumables Market, 2020-2030 (USD Million)
  • Figure 17.5: 3D Cell Culture Services Market, 2020-2030 (USD Million)
  • Figure 17.6: Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2020-2030
  • Figure 17.7: 3D Cell Culture Systems Market for Scaffold Based Products, 2020-2030 (USD Million)
  • Figure 17.8: 3D Cell Culture Systems Market for Scaffold Free Products, 2020-2030 (USD Million)
  • Figure 17.9: 3D Cell Culture Systems Market for 3D Bioreactors, 2020-2030 (USD Million)
  • Figure 17.10: Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2020 and 2030
  • Figure 17.11: 3D Cell Culture Systems Market for Attachment Resistant Surfaces, 2020-2030 (USD Million)
  • Figure 17.12: 3D Cell Culture Systems Market for Hydrogels / ECMs, 2020-2030 (USD Million)
  • Figure 17.13: 3D Cell Culture Systems Market for Micropatterned Surface, 2020-2030 (USD Million)
  • Figure 17.14: 3D Cell Culture Systems Market for Microcarriers, 2020-2030 (USD Million)
  • Figure 17.15: 3D Cell Culture Systems Market for Microfluidic Systems, 2020-2030 (USD Million)
  • Figure 17.16: 3D Cell Culture Systems Market for Solid Scaffolds, 2020-2030 (USD Million)
  • Figure 17.17: 3D Cell Culture Systems Market for Suspension Cultures, 2020-2030 (USD Million)
  • Figure 17.18: Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2020 and 2030
  • Figure 17.19: 3D Cell Culture Systems Market for Cancer Research, 2020-2030 (USD Million)
  • Figure 17.20: 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, 2020-2030 (USD Million)
  • Figure 17.21: 3D Cell Culture Systems Market for Stem Cell Research, 2020-2030 (USD Million)
  • Figure 17.22: 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, 2020-2030 (USD Million)
  • Figure 17.23: Global 3D Cell Culture Systems Market: Distribution by Purpose, 2020-2030
  • Figure 17.24: 3D Cell Culture Systems Market for Research Use, 2020-2030 (USD Million)
  • Figure 17.25: 3D Cell Culture Systems Market for Therapeutic Use, 2020-2030 (USD Million)
  • Figure 17.26: Global 3D Cell Culture Systems Market: Distribution by Geography, 2020- 2030
  • Figure 17.27: 3D Cell Culture Systems Market in North America, 2020-2030 (USD Million)
  • Figure 17.28: 3D Cell Culture Systems Market in Europe, 2020-2030 (USD Million)
  • Figure 17.29: 3D Cell Culture Systems Market in Asia-Pacific, 2020-2030 (USD Million)
  • Figure 17.30: 3D Cell Culture Systems Market in Latin America, 2020-2030 (USD Million)
  • Figure 17.31: 3D Cell Culture Systems Market in Middle East and North Africa (MENA), 2020-2030 (USD Million)
  • Figure 17.32: 3D Cell Culture Systems Market in Rest of the World, 2020-2030 (USD Million)
  • Figure 17.33: Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
  • Figure 17.34: Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
  • Figure 18.1: Survey Insights: Distribution of Respondents by Year of Establishment of the Company
  • Figure 18.2: Survey Insights: Distribution of Respondents by Company Size
  • Figure 18.3: Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
  • Figure 18.4: Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
  • Figure 18.5: Survey Insights: Distribution of Respondents by Designation and Seniority Level
  • Figure 18.6: Survey Insights: Distribution by Focus Area
  • Figure 18.7: Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
  • Figure 18.8: Survey Insights: Distribution by Status of Development of Product(s)
  • Figure 18.9: Survey Insights: Distribution by Method of Fabrication Used
  • Figure 18.10: Survey Insights: Distribution by Source of Cultured Cells
  • Figure 18.11: Survey Insights: Distribution by Key Applications
  • Figure 18.12: Survey Insights: Distribution by 3D Cell Culture Services Offered
  • Figure 18.13: Survey Insights: Distribution by Current and Future Market Opportunity, 2020 and 2030
  • Figure 19.1: 3D Cell Culture Systems Market: Concluding Remarks

List Of Tables

  • Table 3.1: Morphology of Cells in a Culture
  • Table 3.2: Differences between 2D and 3D Cell Cultures
  • Table 3.3: Features of 3D Spheroids generated via 3D Cell Culture Systems
  • Table 4.1: Advantages and Disadvantages of Scaffold Based and Scaffold Free Systems
  • Table 4.2: Advantages and Disadvantages of Natural and Synthetic Scaffolds
  • Table 4.3: Advantages and Disadvantages of Natural and Synthetic Hydrogels
  • Table 4.4: Cell Cultures Used in Magnetic Levitation
  • Table 4.5: Origin and Culture Techniques Used for Organoids
  • Table 5.1: Advantages and Disadvantages of Methods Used for Fabrication for Porous Scaffolds
  • Table 5.2: 3D Cell Culture Studies Using Porous Scaffolds
  • Table 5.3: Methods for Fabrication Used of Fibrous Scaffolds
  • Table 5.4: Advantages and Disadvantages of Methods Used for Fabrication of Fibrous Scaffolds
  • Table 5.5: 3D Cell Culture Studies Using Fibrous Scaffolds
  • Table 5.6: Advantages and Disadvantages of Methods Used for Fabrication of Hydrogels
  • Table 5.7: 3D Cell Culture Studies Using Hydrogels
  • Table 5.8: Advantages and Disadvantages of Methods Used for Fabrication of Custom Scaffolds
  • Table 5.9: 3D Cell Culture Studies Using Custom Scaffolds
  • Table 5.10: Advantages and Disadvantages of Methods Used for Fabrication of Microspheres
  • Table 5.11: 3D Cell Culture Studies Using Microspheres
  • Table 5.12: 3D Cell Culture Studies Using Native Scaffolds
  • Table 6.1: 3D Cell Culture Systems: List of Developers
  • Table 6.2: 3D Cell Culture Systems: List of Service Providers
  • Table 6.3: 3D Cell Culture Systems: List of Assays, Kits and Reagents
  • Table 7.1: Scaffold Based Products: List of Products
  • Table 7.2: Scaffold Based Products: List of Developers
  • Table 8.1: Scaffold Free Products: List of Products
  • Table 8.2: Scaffold Free Products: List of Developers
  • Table 9.1: 3D Bioreactors: List of Products
  • Table 9.2: 3D Bioreactors: List of Developers
  • Table 10.1 Scaffold Based Products: Information on Key Application Areas
  • Table 10.2 Scaffold Free Products: Information on Key Application Areas
  • Table 10.3 3D Bioreactors: Information on Key Application Areas
  • Table 11.1: Scaffold Based Products (Hydrogel / ECM): List of Companies Profiled
  • Table 11.2: 3D Biotek: Company Snapshot
  • Table 11.3: 3D Biotek: Key Characteristics of Hydrogels / ECMs
  • Table 11.4: Advanced Biomatrix: Company Snapshot
  • Table 11.5: Advanced Biomatrix: Key Characteristics of Hydrogels / ECMs
  • Table 11.6: Advanced Biomatrix: Recent Developments and Future Outlook
  • Table 11.7: Alphabioregen: Company Snapshot
  • Table 11.8: Alphabioregen: Key Characteristics of Hydrogels / ECMs
  • Table 11.9: Corning Life Sciences: Company Snapshot
  • Table 11.10: Corning Life Sciences: Key Characteristics of Hydrogels / ECMs
  • Table 11.11: Corning Life Sciences: Recent Developments and Future Outlook
  • Table 11.12: REPROCELL: Company Snapshot
  • Table 11.13: REPROCELL: Key Characteristics of Hydrogels / ECMs
  • Table 11.14: REPROCELL: Recent Developments and Future Outlook
  • Table 12.1: Scaffold Free Products (Organ-on-Chip): List of Companies Profiled
  • Table 12.2: CN Bio Innovations: Company Snapshot
  • Table 12.3: CN Bio Innovations: Information on Funding Instances
  • Table 12.4: CN Bio Innovations: Key Characteristics of Organ-on-Chips Products
  • Table 12.5: CN Bio Innovations: Recent Developments and Future Outlook
  • Table 12.6: Emulate: Company Snapshot
  • Table 12.7: Emulate: Information on Funding Instances
  • Table 12.8: Emulate: Key Characteristics of Organ-on-Chips Products
  • Table 12.9: Emulate: Recent Developments and Future Outlook
  • Table 12.10: InSphero: Company Snapshot
  • Table 12.11: InSphero: Information on Funding Instances
  • Table 12.12: InSphero: Key Characteristics of Organ-on-Chips Products
  • Table 12.13: InSphero: Recent Developments and Future Outlook
  • Table 12.14: Mimetas: Company Snapshot
  • Table 12.15: Mimetas: Information on Funding Instances
  • Table 12.16: Mimetas: Key Characteristics of Organ-on-Chips Products
  • Table 12.17: Mimetas: Recent Developments and Future Outlook
  • Table 12.18: Mimetas: Company Snapshot
  • Table 12.19: Mimetas: Information on Funding Instances
  • Table 12.20: Mimetas: Key Characteristics of Organ-on-Chips Products
  • Table 12.21: Mimetas: Recent Developments and Future Outlook
  • Table 12.22: TissUse: Company Snapshot
  • Table 12.23: TissUse: Key Characteristics of Organ-on-Chips Products
  • Table 12.24: TissUse: Recent Developments and Future Outlook
  • Table 13.1: 3D Bioreactors: List of Companies Profiled
  • Table 13.2: BISS TGT: Company Snapshot
  • Table 13.3: BISS TGT: Key Characteristics of 3D Bioreactors
  • Table 13.4: BISS TGT: Recent Developments and Future Outlook
  • Table 13.5: Celartia: Company Snapshot
  • Table 13.6: Celartia: Key Characteristics of 3D Bioreactors
  • Table 13.7: Cell Culture: Company Snapshot
  • Table 13.8: Cell Culture: Key Characteristics of 3D Bioreactors
  • Table 13.9: CESCO Bioengineering: Company Snapshot
  • Table 13.10: CESCO Bioengineering: Key Characteristics of 3D Bioreactors
  • Table 13.11: EBERS: Company Snapshot
  • Table 13.12: EBERS: Key Characteristics of 3D Bioreactors
  • Table 13.13: EBERS: Recent Developments and Future Outlook
  • Table 13.14: Flexcell International: Company Snapshot
  • Table 13.15: Flexcell International: Key Characteristics of 3D Bioreactors
  • Table 13.16: PBS Biotech: Company Snapshot
  • Table 13.17: PBS Biotech: Key Characteristics of 3D Bioreactors
  • Table 13.18: Synthecon: Company Snapshot
  • Table 13.19: Synthecon: Key Characteristics of 3D Bioreactors
  • Table 14.1: Funding and Investments: Information on Year of Investment, Type of Funding, Amount Raised and Investor, 2015 - Q3 2020
  • Table 14.2: Funding and Investments: Information on Year of Establishment, Location of Headquarters of Recipients, Focus Area, and Type of Product, 2015 - Q3 2020
  • Table 15.1: Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership Model, and Partner, 2015 - Q3 2020
  • Table 15.2: Partnerships and Collaborations: Information on Type of Agreement, Focus Area, and Type of Product, 2015 - Q3 2020
  • Table 16.1: Patent Analysis: CPC Symbols
  • Table 16.2: Patent Analysis: Most Popular CPC Symbols
  • Table 16.3: Patent Analysis: List of Top 10 CPC Symbols
  • Table 16.4: Patent Analysis: List of Relatively High Value Patents
  • Table 17.1: Global 3D Cell Culture Systems Market: Key Assumptions Related to Distribution by Type of Products
  • Table 18.1: Survey Insights: Overview of Respondents
  • Table 18.2: Survey Insights: Designation and Seniority Level
  • Table 18.3: Survey Insights: Focus Area of the Company
  • Table 18.4: Survey Insights: Type of 3D Cell Culture Products Offered
  • Table 18.5: Survey Insights: Status of Development of Product(s)
  • Table 18.6: Survey Insights: Method of Fabrication Used
  • Table 18.7: Survey Insights: Source of 3D Cultured Cells
  • Table 18.8: Survey Insights: Key Areas of Application
  • Table 18.9: Survey Insights: 3D Cell Culture Services Offered
  • Table 18.10: Survey Insights: Current Market Opportunity (2020)
  • Table 18.11: Survey Insights: Future Market Opportunity (2030)
  • Table 20.1: Cellendes: Company Snapshot
  • Table 20.2: Synthecon: Company Snapshot
  • Table 20.3: BRTI Life Sciences: Company Snapshot
  • Table 20.4: Kirkstall: Company Snapshot
  • Table 20.5: QGel: Company Snapshot
  • Table 20.6: Xylyx Bio: Company Snapshot
  • Table 20.7: InSphero: Company Snapshot
  • Table 20.8: GSI: Company Snapshot
  • Table 20.9: Nanofiber Solutions: Company Snapshot
  • Table 21.1: 3D Cell Culture 7System Developers: Distribution by Year of Establishment
  • Table 21.2: 3D Cell Culture System Developers: Distribution by Company Size
  • Table 21.3: 3D Cell Culture System Developers: Distribution by Location of Headquarters
  • Table 21.4: 3D Cell Culture System Developers: Distribution by 3D Cell Culture Format
  • Table 21.5: 3D Cell Culture System Developers: Distribution by Type of Product
  • Table 21.6: 3D Cell Culture System Developers: Distribution by Number of Products
  • Table 21.7: Heat Map Representation: Distribution by 3D Cell Culture Format and Location of Headquarters
  • Table 21.8: Tree Map Representation: Distribution by Company Size and Type of Product
  • Table 21.9: World Map Representation: Distribution by Location of Regional Headquarters
  • Table 21.10: Scaffold Based Products: Distribution by Status of Development
  • Table 21.11: Scaffold Based Products: Distribution by Type of Product
  • Table 21.12: Scaffold Based Products: Distribution by Source of 3D Cultured Cells
  • Table 21.13: Scaffold Based Products: Distribution by Method Used for Fabrication
  • Table 21.14: Scaffold Based Products: Distribution by Material Used for Fabrication
  • Table 21.15: Scaffold Based Products: Distribution by Type of Product and Source of 3D Cultured Cells
  • Table 21.16: Scaffold Based Products: Distribution by Type of Product and Method Used for Fabrication
  • Table 21.17: Scaffold Based Product Developers: Distribution by Year of Establishment
  • Table 21.18: Scaffold Based Product Developers: Distribution by Company Size
  • Table 21.19: Scaffold Based Product Developers: Distribution by Location of Headquarters
  • Table 21.20: Leading Developers: Distribution by Number of Scaffold Based Products
  • Table 21.21: Tree Map Representation: Distribution by Type of Product and Company Size
  • Table 21.22: Scaffold Free Products: Distribution by Status of Development
  • Table 21.23: Scaffold Free Products: Distribution by Type of Product
  • Table 21.24: Scaffold Free Products: Distribution by Source of 3D Cultured Cells
  • Table 21.25: Scaffold Free Products: Distribution by Method Used for Fabrication
  • Table 21.26: Scaffold Free Products: Distribution by Material Used for Fabrication
  • Table 21.27: Scaffold Free Products: Distribution by Type of Product and Source of 3D Cultured Cells
  • Table 21.28: Scaffold Free Products: Distribution by Type of Product and Method Used for Fabrication
  • Table 21.29: Scaffold Free Product Developers: Distribution by Year of Establishment
  • Table 21.30: Scaffold Free Product Developers: Distribution by Company Size
  • Table 21.31: Scaffold Free Product Developers: Distribution by Location of Headquarters
  • Table 21.32: Leading Developers: Distribution by Number of Scaffold Free Products
  • Table 21.33: Tree Map Representation: Distribution by Type of Product and Company Size
  • Table 21.34: 3D Bioreactors: Distribution by Type of 3D Bioreactor
  • Table 21.35: 3D Bioreactors: Distribution by Working Volume
  • Table 21.36: 3D Bioreactor Developers: Distribution by Year of Establishment
  • Table 21.37: 3D Bioreactor Developers: Distribution by Company Size
  • Table 21.38: 3D Bioreactor Developers: Distribution by Location of Headquarters
  • Table 21.39: Leading Developers: Distribution by Number of 3D Bioreactors
  • Table 21.40: 3D Cell Culture Systems: Distribution by Key Application Areas
  • Table 21.41: 3D Cell Culture Systems: Distribution by Key Application Areas and 3D Cell Culture Format
  • Table 21.42: Scaffold Based Products: Distribution by Key Application Areas
  • Table 21.43: Scaffold Free Products: Distribution by Key Application Areas
  • Table 21.44: 3D Bioreactors: Distribution by Key Application Areas
  • Table 21.45: Funding and Investments: Distribution of Recipient Companies by Year of Establishment and Type of Funding, 2015-Q3 2020
  • Table 21.46: Funding and Investments: Cumulative Number of Instances by Year, 2015-Q3 2020
  • Table 21.47: Funding and Investments: Cumulative Amount Invested, 2015-Q3 2020 (USD Million)
  • Table 21.48: Funding and Investments: Distribution of Instances by Type of Funding, 2015-Q3 2020
  • Table 21.49: Funding and Investments: Year-Wise Distribution by Number of Instances and Type of Funding, 2015 - Q3 2020
  • Table 21.50: Funding and Investments: Distribution of Amount Invested by Type of Funding, 2015 - Q3 2020 (USD Million)
  • Table 21.51: Funding and Investments: Year-Wise Distribution of Amount Invested and Type of Funding, 2015 - Q3 2020
  • Table 21.52: Funding and Investments: Distribution of Instances and Amount Invested by 3D Cell Culture Format, 2015-Q3 2020
  • Table 21.53: Funding and Investments: Distribution of Instances and Amount Invested by Type of Product, 2015-Q3 2020
  • Table 21.54: Funding and Investments: Distribution by Geography
  • Table 21.55: Funding and Investments: Regional Distribution by Total Amount Invested, 2015-Q3 2020
  • Table 21.56: Most Active Players: Distribution by Number of Funding Instances, 2015-Q3 2020
  • Table 21.57: Most Active Players: Distribution by Amount Raised, 2015-Q3 2020 (USD Million)
  • Table 21.58: Most Active Investors: Distribution by Funding Instances, 2015-Q3 2020
  • Table 21.59: Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-Q3 2020
  • Table 21.60: Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 21.61: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Table 21.62: Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
  • Table 21.63: Partnerships and Collaborations: Distribution by Type of Partner
  • Table 21.64: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Table 21.65: Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 21.66: Partnerships and Collaborations: Distribution by 3D Cell Culture Format
  • Table 21.67: Partnerships and Collaborations: Distribution by Year of Partnership and 3D Cell Culture Format
  • Table 21.68: Partnerships and Collaborations: Distribution by Type of Partnership and 3D Cell Culture Format
  • Table 21.69: Partnerships and Collaborations: Distribution by Type of Product
  • Table 21.70: Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
  • Table 21.71: Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
  • Table 21.72: Most Active Players: Distribution by Number of Partnerships
  • Table 21.73: Partnerships and Collaborations: Regional Distribution
  • Table 21.74: Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 21.75: Patent Analysis: Distribution by Type of Patent
  • Table 21.76: Patent Analysis: Cumulative Distribution by Publication Year, 2015-Q3 2020
  • Table 21.77: Patent Analysis: Distribution of Granted Patents by Publication Year, 2015-Q3 2020
  • Table 21.78: Patent Analysis: Distribution of Filed Patents Publication Year, 2015-Q3 2020
  • Table 21.79: Patent Analysis: Distribution by Number of Patent Type and Publication Year, 2015-Q3 2020
  • Table 21.80: Patent Analysis: Distribution by Issuing Authorities Involved
  • Table 21.81: Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2015-Q3 2020
  • Table 21.82: Leading Patent Assignees (Industry Players): Distribution by Number of Patents
  • Table 21.83: Leading Patent Assignees (Non-Industry Players): Distribution by Number of Patents
  • Table 21.84: Patent Analysis: Distribution by Patent Age, 2000-2020
  • Table 21.85: Patent Analysis: Valuation Analysis
  • Table 21.86: Global 3D Cell Culture Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.87: Global 3D Cell Culture Market: Distribution by Business Segment, 2020 and 2030
  • Table 21.88: 3D Cell Culture Systems Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.89: 3D Cell Culture Consumables Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.90: 3D Cell Culture Services Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.91: Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format, 2020 and 2030
  • Table 21.92: 3D Cell Culture Systems Market for Scaffold based Products, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.93: 3D Cell Culture Systems Market for Scaffold Free Products, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.94: 3D Cell Culture Systems Market for Market 3D Bioreactors, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.95: Global 3D Cell Culture Systems Market: Distribution by Type of Product, 2020 and 2030
  • Table 21.96: 3D Cell Culture Systems Market for Attachment Resistant Surfaces, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.97: 3D Cell Culture Systems Market for Hydrogels / ECMs, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.98: 3D Cell Culture Systems Market for Micropatterned Surface, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.99: 3D Cell Culture Systems Market for Microcarriers, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.100: 3D Cell Culture Systems Market for Microfluidic Systems, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.101: 3D Cell Culture Systems Market for Solid Scaffolds, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.102: 3D Cell Culture Systems Market for Suspension Culture Systems, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.103: Global 3D Cell Culture Systems Market: Distribution by Area of Application, 2020 and 2030
  • Table 21.104: 3D Cell Culture Systems Market for Cancer Research, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.105: 3D Cell Culture Systems Market for Drug Discovery and Toxicity Testing, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.106: 3D Cell Culture Systems Market for Stem Cell Research, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.107: 3D Cell Culture Systems Market for Regenerative Medicine and Tissue Engineering, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.108: Global 3D Cell Culture Systems Market: Distribution by Purpose, 2020 and 2030
  • Table 21.109: 3D Cell Culture Systems Market for Research Use, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.110: 3D Cell Culture Systems Market for Therapeutic Use, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.111: Global 3D Cell Culture Systems Market: Distribution by Geography, 2020 and 2030
  • Table 21.112: 3D Cell Culture Systems Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.113: 3D Cell Culture Systems Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.114: 3D Cell Culture Systems Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.115: 3D Cell Culture Systems Market in Latin America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.116: 3D Cell Culture Systems Market in Middle East and North Africa (MENA), Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.117: 3D Cell Culture Systems Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Million)
  • Table 21.118: Global 3D Cell Culture Systems Market: Distribution by Leading Players, 2020
  • Table 21.119: Global 3D Cell Culture Systems Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
  • Table 21.120: Survey Insights: Distribution of Respondents by Year of Establishment of Company
  • Table 21.121: Survey Insights: Distribution of Respondents by Company Size
  • Table 21.122: Survey Insights: Distribution of Respondents by Location of Company Headquarters (Region-Wise)
  • Table 21.123: Survey Insights: Distribution of Respondents by Location of Company Headquarters (Country-Wise)
  • Table 21.124: Survey Insights: Distribution of Respondents by Designation and Seniority Level
  • Table 21.125: Survey Insights: Distribution by Focus Area
  • Table 21.126: Survey Insights: Distribution by Type of 3D Cell Culture Products Offered
  • Table 21.127: Survey Insights: Distribution by Development Status of Product(s)
  • Table 21.128: Survey Insights: Distribution by Method of Fabrication Used
  • Table 21.129: Survey Insights: Distribution by Source of Cultured Cells
  • Table 21.130: Survey Insights: Distribution by Key Application Areas
  • Table 21.131: Survey Insights: Distribution by 3D Cell Culture Services Offered
  • Table 21.132: Survey Insights: Distribution by Current and Future Market Opportunity, 2020 and 2030

List Of Company

The following companies / organizations have been mentioned in this report.

  • 1. 101Bio
  • 2. 3D Biomatrix
  • 3. 3D Biotek
  • 4. 3D Biotechnology Solutions
  • 5. 3Dnamics
  • 6. 4Dcell
  • 7. 4titude
  • 8. AbbVie Ventures
  • 9. abc biopply
  • 10. ABL Europe
  • 11. Abo Akademi University
  • 12. Abstraction Ventures
  • 13. Abzena
  • 14. Accellta
  • 15. Advanced BioMatrix
  • 16. Advanced Regenerative Manufacturing Institute (ARMI)
  • 17. Advanced Scientifics
  • 18. Aetos Biologics
  • 19. Afirmus Biosource
  • 20. AGC
  • 21. Agency for Science, Technology and Research (A*STAR)
  • 22. AIM Biotech
  • 23. Akero Therapeutics
  • 24. Akron Biotech
  • 25. Alector
  • 26. Allevi
  • 27. Alnylam Pharmaceuticals
  • 28. American Laboratory Products
  • 29. Alphabioregen
  • 30. ALS Investment Fund
  • 31. AlveoliX
  • 32. AMS Biotechnology
  • 33. AnaPath Services
  • 34. Angel Investors
  • 35. AngelMD
  • 36. Angels 5K
  • 37. Angels in MedCity
  • 38. Angels Santé
  • 39. Anthrogenesis
  • 40. Aquitaine Science Transfert
  • 41. Aquiti Gestion
  • 42. AR Brown
  • 43. ARL Design
  • 44. ARTeSYN Biosolutions
  • 45. AstraZeneca
  • 46. Arizona State University
  • 47. ATEL Ventures
  • 48. Atera
  • 49. Avantor
  • 50. AxoSim
  • 51. AXT
  • 52. Axxicon
  • 53. BASF
  • 54. Bayer
  • 55. B-CULTURE
  • 56. BEOnChip
  • 57. Bio-Byblos Biomedical
  • 58. BioCat
  • 59. BioConcept
  • 60. BIOFABICS
  • 61. Biogelx
  • 62. Bioinspired Solutions
  • 63. BioInvent International
  • 64. BIOKE
  • 65. BioLamina
  • 66. Biomaterials USA
  • 67. Biomerix
  • 68. BiomimX
  • 69. Biopredic International
  • 70. BioTek Instruments
  • 71. BiSS TGT
  • 72. Bonus BioGroup
  • 73. Bpifrance
  • 74. BRAIN
  • 75. BrainXell
  • 76. Brammer Bio
  • 77. Braveheart Investment Group
  • 78. Bristol-Myers Squibb
  • 79. Broad Institute
  • 80. BRTI Life Sciences
  • 81. Cambridge Bioscience
  • 82. University of Cambridge
  • 83. CarThera
  • 84. Cedars-Sinai Medical Center
  • 85. Celartia
  • 86. Cell Applications
  • 87. Cell Culture
  • 88. CELLEC BIOTEK
  • 89. Cellendes
  • 90. Cellevate
  • 91. CELLnTEC
  • 92. CellSpring
  • 93. CellSystems
  • 94. CelVivo
  • 95. Center for the Advancement of Science in Space
  • 96. CESCO Bioengineering
  • 97. Charles River Laboratories
  • 98. Cherry Biotech
  • 99. China Regenerative Medicine International
  • 100. CITIC Securities
  • 101. CN Bio Innovations
  • 102. CN Innovations
  • 103. Collagen Solutions
  • 104. Comune di Milano
  • 105. Corning Life Sciences
  • 106. Cosmo Bio
  • 107. CELLphenomics
  • 108. Commonwealth Serum Laboratories
  • 109. Curi Bio
  • 110. Cyprio
  • 111. Cyprotex
  • 112. Cytiva
  • 113. Danaher
  • 114. Deepbridge Capital
  • 115. Demcon
  • 116. United States Department of Defense
  • 117. Development Bank of Wales
  • 118. DiPole Materials
  • 119. Downing Ventures
  • 120. Government of the Netherlands
  • 121. Executive Agency for Small and Medium-sized Enterprises (EASME)
  • 122. EBERS
  • 123. Ectica Technologies
  • 124. EDITHGEN
  • 125. Electrospinning
  • 126. Emulate
  • 127. Enso Discoveries
  • 128. Eppendorf
  • 129. Esco Aster
  • 130. Esperante
  • 131. Ethicon
  • 132. European Life Sciences Growth Fund (ELSGF)
  • 133. European Commission
  • 134. European Union
  • 135. Eurostars
  • 136. EU-ToxRisk
  • 137. Eva Scientific
  • 138. Evotec
  • 139. faCellitate
  • 140. Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • 141. Fennik Life Sciences
  • 142. Ferentis
  • 143. FHNW University
  • 144. FiberCell Systems
  • 145. Fibralign
  • 146. Finep
  • 147. Finesse Solutions
  • 148. Finovam Gestion
  • 149. Flexcell International
  • 150. Foundation for Technological Innovation
  • 151. Founder
  • 152. Founders Fund
  • 153. Freeline
  • 154. French Government
  • 155. Frequency Therapeutics
  • 156. FroggaBio
  • 157. Fujifilm
  • 158. FUJIFILM Wako Pure Chemical
  • 159. Funakoshi
  • 160. Gabriel Investments
  • 161. Galapagos
  • 162. GALIA Gestion
  • 163. Gamma 3
  • 164. Gelmetix
  • 165. Gelomics
  • 166. Gemini Bio
  • 167. Gemstone Biotherapeutics
  • 168. Genome Institute of Singapore
  • 169. Georgia Research Alliance
  • 170. Global Cell Solutions
  • 171. Government of China
  • 172. Great Stuff Ventures
  • 173. GSI
  • 174. GlaxoSmithKline
  • 175. HµREL
  • 176. Hamilton
  • 177. Harvard Apparatus
  • 178. Harvard College
  • 179. HCS Pharma
  • 180. Helvoet
  • 181. Heraeus Medical
  • 182. Hesperos
  • 183. Histogenics
  • 184. Human Models for Analysis of Pathways (HMAPs) Center
  • 185. Hokkaido Soda
  • 186. HP Wild Holding
  • 187. Hubrecht Organoid Technology
  • 188. Humanetics
  • 189. Hyamedix
  • 190. ibidi
  • 191. IMSS-Gulf Bio Analytical
  • 192. INITIO CELL
  • 193. Innovate UK
  • 194. Innovation Fund Denmark
  • 195. Inova Health System
  • 196. inRegen
  • 197. InSphero
  • 198. Invitrocue
  • 199. InvivoSciences
  • 200. Ionis Pharmaceuticals
  • 201. Irdi Soridec Gestion
  • 202. Janssen Biotech
  • 203. Japan Vilene Company
  • 204. Jellagen Marine Biotechnologies
  • 205. Johns Hopkins University
  • 206. JRI Orthopaedics
  • 207. Kero
  • 208. Kim & Friends
  • 209. Kirkstall
  • 210. KIYATEC
  • 211. KOKEN
  • 212. Koninklijke Nederlandse Akademie Van Wetenschappen
  • 213. Kuraray
  • 214. LabCorp
  • 215. Laconia
  • 216. LAMBDA Laboratory Instruments
  • 217. Lantern Pharma
  • 218. Lawrence J. Ellison Institute for Transformative Medicine
  • 219. LBA Healthcare Management
  • 220. Lena Biosciences
  • 221. LFB Biomanufacturing
  • 222. Life Technologies
  • 223. Lifecore Biomedical
  • 224. LifeNet Health
  • 225. Laboratory for Integrated Micro Mechatronic Systems
  • 226. Lineage Cell Therapeutics
  • 227. Locate Bio
  • 228. London School of Hygiene & Tropical Medicine
  • 229. Lonza
  • 230. Lund University
  • 231. LuoLabs
  • 232. Manchester BIOGEL
  • 233. University of Mannheim
  • 234. Maryland Momentum Fund
  • 235. Massachusetts Institute of Technology
  • 236. MassChallenge
  • 237. MatTek Life Sciences
  • 238. MBL International
  • 239. GlassWall Syndicate
  • 240. Menicon Life Science
  • 241. Merck Accelerator
  • 242. Merck Millipore
  • 243. Michael J. Fox Foundation
  • 244. Michigan Technological University
  • 245. Micronit
  • 246. MicroTissues
  • 247. Midven
  • 248. MIMETAS
  • 249. Minerva Business Angel Network
  • 250. Molecular Devices
  • 251. Maryland Stem Cell Research Fund (MSCRF)
  • 252. MTTlab
  • 253. Nanobiose
  • 254. Nano Dimension
  • 255. Nanofiber Solutions
  • 256. Nanogaia
  • 257. National Aeronautics and Space Administration
  • 258. National Center for Advancing Translational Sciences
  • 259. National Institute of Health
  • 260. National Institute on Aging
  • 261. National Institutes for Food and Drug Control
  • 262. National Science Foundation
  • 263. National University Hospital
  • 264. National University of Singapore
  • 265. National Centre for the Replacement, Refinement and Reduction of Animals in Research
  • 266. Neuromics
  • 267. New Orleans BioFund
  • 268. Newable Private Investing
  • 269. Nexcelom Bioscience
  • 270. Nord France Amorquage
  • 271. Invest Northern Ireland
  • 272. Northwick Park Institute for Medical Research
  • 273. Nortis
  • 274. Nova Biomedical
  • 275. Novartis Venture Fund
  • 276. Noviocell
  • 277. Nucleus Biologics
  • 278. NYU Winthrop Hospital
  • 279. Olaregen Therapeutix
  • 280. OMNI Life Science
  • 281. Oregon Health & Science University
  • 282. Organovo
  • 283. Orthomimetics
  • 284. OS Fund
  • 285. Oxford MEStar
  • 286. Pairnomix
  • 287. Pall Corporation
  • 288. Path BioAnalytics
  • 289. PBS Biotech
  • 290. Peak Capital Advisors
  • 291. Pelo Biotech
  • 292. Pensees
  • 293. PepGel
  • 294. Percell Biolytica
  • 295. PerkinElmer
  • 296. Pfizer
  • 297. PHI
  • 298. Pitch@Palace
  • 299. PL BioScience
  • 300. Plasticell
  • 301. Pluristem Therapeutics
  • 302. Portugal Ventures
  • 303. Precision Biologics
  • 304. Premedical Laboratories
  • 305. Primorigen Biosciences
  • 306. Principia SGR
  • 307. ProBio
  • 308. ProBioGen
  • 309. Prodizen
  • 310. PromoCell
  • 311. Protista International
  • 312. QGel Bio
  • 313. QIAGEN (Suzhou)
  • 314. Quintech Life Sciences
  • 315. PT Rajawali Medika Mandiri
  • 316. RASA
  • 317. React4life
  • 318. Real Research
  • 319. RealBio Technology
  • 320. Regemat3D
  • 321. Repligen
  • 322. REPROCELL
  • 323. Research Without Animal Experiment
  • 324. Revivocell
  • 325. Rigenerand
  • 326. Roche
  • 327. RoosterBio
  • 328. Roswell Park Comprehensive Cancer Center
  • 329. Sanofi Ventures
  • 330. SARSTEDT
  • 331. Sartorius
  • 332. S-BIO
  • 333. ScienCell
  • 334. SciFi VC
  • 335. SciKon Innovation
  • 336. Scinus Cell Expansion
  • 337. Scottish Investment Bank
  • 338. Seres Therapeutics
  • 339. Shanghai Cienle Medical Technology
  • 340. Shanghai Institute of Materia Medica
  • 341. Shanghai Institute of Biochemistry and Cell Biology
  • 342. Siemens Technology
  • 343. Sigma-Aldrich
  • 344. SKE Research Equipment
  • 345. SmiLe Incubator
  • 346. SoloHill Engineering
  • 347. Spheritech
  • 348. Spiber Technologies
  • 349. Start-Up Chile
  • 350. State Key Laboratory of Experimental Hematology
  • 351. StemCell Systems
  • 352. STEMCELL Technologies
  • 353. Stemmatters
  • 354. StemoniX
  • 355. StemTek Therapeutics
  • 356. SUN bioscience
  • 357. Commission for Technology and Innovation
  • 358. Swiss Federal Laboratories for Materials Science and Technology
  • 359. SyndicateRoom
  • 360. Synthecon
  • 361. SynVivo
  • 362. TA Instruments
  • 363. Takeda
  • 364. Tantti Laboratory
  • 365. tebu-bio
  • 366. TEDCO
  • 367. Terumo
  • 368. Texas Tech University Health Sciences Center
  • 369. Development Bank of Wales
  • 370. Ministry of Higher Education, Research and Innovation (France)
  • 371. The Idea Village
  • 372. Institute for Molecular Medicine Finland
  • 373. Mario Negri Institute for Pharmacological Research
  • 374. University of Alberta
  • 375. University of Bath
  • 376. University of Brescia
  • 377. University of Bristol
  • 378. University of Manchester
  • 379. University of Milan
  • 380. University of Strathclyde
  • 381. University of Zurich
  • 382. TheWell Bioscience
  • 383. Thermo Fisher Scientific
  • 384. Tianjin Weikai Biological Engineering
  • 385. Tissue Click
  • 386. TissueLabs
  • 387. TissUse
  • 388. Tokyo Future Style
  • 389. TPG
  • 390. TreeFrog Therapeutics
  • 391. Trevigen
  • 392. Triumvirate Environmental
  • 393. Technical University of Berlin
  • 394. Twinhelix
  • 395. UK Innovation & Science Seed Fund
  • 396. Science and Technology Facilities Council (STFC)
  • 397. UK Science and Technology Facilities Council
  • 398. University of Genoa
  • 399. University College London
  • 400. University Hospital Zurich
  • 401. Stanford University
  • 402. University of Arkansas for Medical Sciences
  • 403. University of California
  • 404. University of Central Florida
  • 405. University of Nottingham
  • 406. The University of Sheffield
  • 407. University of Washington School of Pharmacy
  • 408. University of Zurich
  • 409. UPM Biomedicals
  • 410. U.S. Small Business Administration
  • 411. UW Medicine
  • 412. VA Portland Health Care System
  • 413. Vanderbilt University
  • 414. Venture Kick
  • 415. VentureSouth
  • 416. Venturecraft
  • 417. Viscofan BioEngineering
  • 418. Visikol
  • 419. Vivo Biosciences
  • 420. VWR
  • 421. Wake Forest Institute for Regenerative Medicine
  • 422. Women Who Tech
  • 423. XAnge
  • 424. Xenos
  • 425. XP Biomed
  • 426. Xylyx Bio
  • 427. Zhejiang University
  • 428. zPREDICTA